AUTHORS
Shaniza Haniff, MD MPH, Jayasree Krishnan, MD, MSPH2, Ashwin Shive Gowda, MBBS3, Rahul Kumar Thakur, MD4, Ajinkya Buradkar, MD, MBBS5, Wajeeha Aiman, MD6, Matthew J. Cortese, MD, MPH7
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 University of Buffalo, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
BACKGROUND: Diffuse large B-cell lymphoma-type Richter transformation (RT-DLBCL) is a high-risk complication of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Prior studies have reported poor median overall survival (OS), but multicenter real-world outcomes by specific prior targeted therapy exposures remain poorly characterized. We evaluated RT-DLBCL outcomes by prior exposure to Bruton tyrosine kinase inhibitors (BTKi) and to venetoclax, a B-cell lymphoma 2 inhibitor (BCL2i), and characterized post-transformation treatment patterns.
METHODS: We conducted retrospective cohort analyses utilizing TriNetX, a multicenter real-world database of de-identified electronic health records. Adult patients (pts) with CLL/SLL who developed RT-DLBCL were categorized as BTKi-exposed without venetoclax (BTK-E), venetoclax-exposed without BTKi (BCL2-E), double-exposed to both classes (DE), or neither-exposed (NE). Each exposed cohort was propensity-score matched 1:1 to the NE cohort using 25 baseline covariates, including age, sex, race/ethnicity, cytopenias, chronic kidney disease, cardiovascular and metabolic comorbidities, and prior anti-CD20 and cytotoxic therapy. The primary endpoint was OS from RT-DLBCL diagnosis through 3 years. Time to next treatment (TTNT), defined as the interval from RT-DLBCL diagnosis to the first recorded therapy or death, was a secondary outcome. Analyses included Kaplan-Meier, log-rank, and Cox proportional hazards models. Treatments documented within 90 days after RT-DLBCL diagnosis were also analyzed in the DE and NE cohorts.
RESULTS: After 1:1 propensity-score matching, the analyses included 399 BTK-E, 106 BCL2-E, and 138 DE, each with a separately matched NE comparator. Mean age across the exposed cohorts ranged from 67.2 to 69.1 years, and 58.1%–68.8% were male.
Previous exposure to targeted therapy was consistently associated with inferior survival following the diagnosis of RT-DLBCL. In the BTK-E cohort, the 3-year OS was 45.2%, compared to 61% among matched NE pts (HR, 1.63; 95% CI, 1.30–2.05; P<0.0001). In the BCL2-E cohort, the 3-year OS was 41.6% versus 65.9% among matched NE pts (HR, 1.83; 95% CI, 1.17–2.87; P=0.0075). The poorest outcomes were observed in the DE pts, with a 3-year OS of 29.2% compared to 58.1%, and all-cause mortality rates of 60.9% versus 36.2% when compared to NE pts. DE pts exhibited the largest absolute difference in mortality (24.6%) and the highest hazard of death (HR, 2.22; 95% CI, 1.56–3.16; P<0.0001). The median OS was 889 days for BTK-E pts, 686 days for BCL2-E pts, and 341 days for DE pts.
The median TTNT was shorter in each exposed cohort: 21 versus 120 days in the BTK-E group, 25 versus 69 days in the BCL2-E group, and 11 versus 42 days in the DE group (all P≤0.0018). Within 90 days of diagnosis, antineoplastic therapy was recorded in 77% of DE pts compared to 38% of NE pts. The most frequently recorded agents in DE versus NE pts were cyclophosphamide (40% vs 19%), rituximab (39% vs 23%), doxorubicin (35% vs 17%), and vincristine (33% vs 17%).
CONCLUSIONS: Prior BTKi or BCL2i treatment was associated with inferior survival outcomes after RT-DLBCL, with DE pts constituting the highest-risk group. Nearly two-thirds of DE pts died within 3 years, and the median OS was approximately 11 months. These findings underscore the urgent clinical need for RT-DLBCL management after targeted therapy and support early referral to clinical trials and the development of novel treatment strategies.
DISCLOSURES
Shaniza Haniff, MD MPH: No relevant conflicts of interest to declare.